ストックスクリーナーアプリを入手
6.16
0.96%
-0.06
アフターアワーズ：
6.16
前日終値:
$6.22
開ける：
$6.23
24時間の取引高:
374.04K
Relative Volume:
1.02
時価総額：
$239.85M
収益：
$5.74M
当期純損益:
$-166.12M
株価収益率:
-1.5408
EPS:
-3.9978
ネットキャッシュフロー:
$-131.64M
1週間 パフォーマンス:
-8.74%
1か月 パフォーマンス:
-19.16%
6か月 パフォーマンス:
-48.88%
1年 パフォーマンス:
+10.39%
1日の値動き範囲:
$6.01
$6.245
1週間の範囲:
$6.01
$6.9299
52週間の値動き範囲:
$5.55
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
名前
Entrada Therapeutics Inc
セクター
電話
857-305-1825
住所
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.16 | 239.85M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-02-11 | 開始されました | Guggenheim | Buy |
| 2026-01-28 | 開始されました | Oppenheimer | Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-01-05 | 開始されました | Oppenheimer | Outperform |
| 2023-04-03 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Entrada Therapeutics Inc (TRDA) 最新ニュース
Why (TRDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Entrada Therapeutics (TRDA) Holds Flat at $6.88 as Traders Eye $6.54 Support and $7.22 ResistanceTrading Ideas - careplusvn.com
Responsive Playbooks and the TRDA Inflection - Stock Traders Daily
MPM BioVentures 2014, L.P. Offloads 259,837 Shares of Entrada Therapeutics (NASDAQ: TRDA) at $7.11-$7.41 Each - Kalkine Media
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Australia
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program - The Manila Times
Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock - Investing.com
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares - Investing.com
Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock By Investing.com - Investing.com Canada
MPM funds sell Entrada (TRDA) shares, still hold stakes over 1.7M each - Stock Titan
MPM funds sell 259,837 Entrada Therapeutics (TRDA) shares over 3 days - Stock Titan
Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead By Investing.com - Investing.com South Africa
MPM BIOVENTURES 2018, L.P. Disposes 86,482 Shares of Entrada Therapeutics Between September 1-3, 2026 - Kalkine Media
Entrada Therapeutics' R&D President Sethuraman Natarajan Forfeits 2,079 Shares at $7.14 Each on September 2, 2026 - Kalkine Media
Entrada Therapeutics CFO Wentworth Kory James Forfeits 1,733 Shares at $7.14 Each (NASDAQ: TRDA) - Kalkine Media
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com South Africa
TRDAEntrada Therapeutics Inc Revenue Breakdown - Finviz
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Canada
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics - Investing.com
MPM BioVentures 2014 reports Entrada Therapeutics common stock sale worth $621,585.04 - Bitget
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days - Stock Titan
MPM funds sell Entrada (TRDA) shares without 10b5-1 plan - Stock Titan
Entrada Therapeutics (TRDA) CEO sale is tax-driven, still owns 517,290 shares - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) CFO stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) insider stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) COO holdings - Stock Titan
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Liquidity Mapping Around (TRDA) Price Events - news.stocktradersdaily.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock By Investing.com - Investing.com UK
Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock By Investing.com - Investing.com Nigeria
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock - Investing.com
Entrada Therapeutics (NASDAQ: TRDA) insider sells near $7 a share - Stock Titan
Entrada Therapeutics (TRDA) backer MPM funds sell 86,914 shares around $7 - Stock Titan
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock By Investing.com - Investing.com India
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock By Investing.com - Investing.com Australia
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock - Investing.com
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and SpaceX (SPCX) - The Globe and Mail
Entrada (TRDA) Results Breakdown: Reported EPS Tops Expectations at the Close; Investor Response: Shares Move 2.31% Lower at the CloseShare Repurchase Impact - vinanet.vn
Entrada (TRDA) Earnings Update: Profit Per Share Surpasses Its Benchmark on the Day; Share Move: Shares Move Higher 7.02%Analyst Earnings Estimate - vinanet.vn
Entrada (TRDA) Earnings Update: Profit Per Share Surpasses Its Benchmark on the Day - careplusvn.com
Entrada Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
(TRDA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Analysts Lower Earnings Estimates for TRDA - marketbeat.com
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares By Investing.com - Investing.com India
Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock - TipRanks
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares - Investing.com India
Entrada Therapeutics Inc (TRDA) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):